Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:4.1.1.6 (CAD)
 4,420 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A major factor contributing to cardiovascular mortality in type 2 diabetes is dyslipidemia, characterized by low HDL cholesterol and high triglycerides, rather than elevated LDL cholesterol. Lipoprotein lipase (LPL) is the rate-limiting enzyme of triglyceride removal from plasma and has been implicated in atherosclerosis. Since treatment with statins significantly reduces cardiovascular morbidity in diabetes, we analyzed the lipid profile and LPL activities in 61 patients with type 2 diabetes before and 8 weeks after initiation of atorvastatin (40 mg) or placebo treatment. Lipid parameters and LPL activity were unchanged under treatment with placebo. Atorvastatin treatment resulted in a 30% reduction of total and a 45% reduction of LDL cholesterol (6.06 +/- 1.39 mmol/L versus 4.14 +/- 1.27 mmol/L and 4.11 +/- 1.13 mmol/L versus 2.27 +/- 0.89 mmol/L, both P < 0.0001). Triglycerides and VLDL cholesterol were also significantly reduced by statin therapy (2.24 +/- 2.11 mmol/L versus 1.82 +/- 1.46 mmol/L and 1.08 +/- 1.56 mmol/L versus 0.67 +/- 0.66 mmol/L, both P < 0.05). HDL cholesterol was not different between the atorvastatin and the placebo group. Compared to baseline, LPL activity was increased by 25% after atorvastatin treatment (213.0 +/- 28.1 nmol/mL/min versus 171.9 +/- 17.7 nmol/mL/min, P < 0.01). Our data demonstrate that atorvastatin induces a significant improvement of diabetic dyslipidemia and a significant increase of LPL activity. Since low LPL activity indicates an increased cardiovascular risk, the statin-mediated increase in LPL activity may help to explain the reduction of CAD in diabetic patients treated with statins.
 ...
PMID:Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. 1526 89

Lipoprotein lipase (LPL) plays a central role in dyslipidemia and development of metabolic syndrome. The occurrence of polymorphisms of the LPL gene may result in the disturbance in the lipid metabolism and pathogenesis of CAD. Carriers of X447 allele were reported to have lower triglyceride and higher high-density lipoprotein cholesterol levels as well as a reduced risk of CAD. The patiens with hypertriglicerydemia are carriers of common PLP mutations as Asp9Asn,Asn291Ser, Trp86Arg, Gly188Glu, Pro207Leu, and Asp250Asn. LPL is an interesting enzyme that contributes in a pronounced way to normal metabolism, including insulin action, body weight regulation, energy balance, and atherosclerosis. In this rewiev, the roles of polymorphism LPL and their implications in the control of lipoprotein metabolism and atherosclerosis are discussed, especially in the group of risk developing metabolic syndrome - children with low birth weight (below 2500 g).
 ...
PMID:[Polymorphisms of lipoprotein lipase gene and their participation in metabolic processes]. 2172 17